Tracers / [18F]NOTA-ABY-030

[18F]NOTA-ABY-030

Also written as [18F]NOTA-ABY-030; [F-18]NOTA-ABY-030
Radionuclide
F-18 t½ 109.77 min
Modality
PET
Production route
—
Stage
—
Syntheses indexed
1
Head and neck cancer

What it is

Compound class
small biologic targeting vector (Affibody) labeled with [18F]NOTA via aluminum fluoride
Target / mechanism
Epidermal Growth Factor Receptor (EGFR) PMID 42423882
Clinical application
Head and Neck Squamous Cell Carcinoma (HNSCC) PMID 42423882
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
———47 ± 10%>90%NOTA-ABY-03042423882
2026 Mol Imaging Biol
GE HealthCare FASTlab cassette-based automated radiosynthesis system — radiochemical yield of 47 ± 10% (n = 3)

Need this precursor?We can point you to suppliers for [18F]NOTA-ABY-030, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
—
USP monograph
—
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]NOTA-ABY-030.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with F-18.